TY - JOUR
T1 - Similar Overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia
AU - Peffault de Latour, Régis
AU - Brunstein, Claudio G.
AU - Porcher, Raphael
AU - Chevallier, Patrice
AU - Robin, Marie
AU - Warlick, Erica
AU - Xhaard, Alienor
AU - Ustun, Celalettin
AU - Larghero, Jérôme
AU - Dhedin, Nathalie
AU - Mohty, Mohamad
AU - Socié, Gerard
AU - Weisdorf, Daniel
PY - 2013/9
Y1 - 2013/9
N2 - For older patients with acute myeloid leukemia (AML), allogeneic hematopoietic cell transplantation (HCT) provides the best chance of long-term survival. A formal comparison between matched sibling (SIB), unrelated donor (URD), or umbilical cord blood (UCB) transplantation has not yet been reported in this setting. We compared reduced-intensity conditioning HCT in 197 consecutive patients 50years and older with AML in complete remission from SIB (n=82), URD (n=35), or UCB (n=80) transplantation. The 3-year cumulative incidences of transplantation-related mortality were 18%, 14%, and 24% with SIB, URD, and UCB transplantation, respectively (. P=.22). The 3-year leukemia-free survival rates were 48%, 57%, and 33% with SIB, URD, and UCB transplantation, respectively (. P=.009). In multivariate analysis, poor-risk cytogenetics was associated with relapse (hazard ratio, 1.7 [95% confidence interval, 1.0 to 3.0]; P=.04) and worse leukemia-free survival (hazard ratio, 1.6 [95% confidence interval, 1.0 to 2.5]; P=.03), whereas donor choice had no significant impact on overall survival (. P=.73). Adjusted 3-year overall survival rates were 55% with SIB, 45% with URD, and 43% with UCB transplantation (. P=.26). Until prospective studies are completed, this study supports the recommendation to consider SIB donor, URD, or UCB for HCT for older patients with AML in complete remission.
AB - For older patients with acute myeloid leukemia (AML), allogeneic hematopoietic cell transplantation (HCT) provides the best chance of long-term survival. A formal comparison between matched sibling (SIB), unrelated donor (URD), or umbilical cord blood (UCB) transplantation has not yet been reported in this setting. We compared reduced-intensity conditioning HCT in 197 consecutive patients 50years and older with AML in complete remission from SIB (n=82), URD (n=35), or UCB (n=80) transplantation. The 3-year cumulative incidences of transplantation-related mortality were 18%, 14%, and 24% with SIB, URD, and UCB transplantation, respectively (. P=.22). The 3-year leukemia-free survival rates were 48%, 57%, and 33% with SIB, URD, and UCB transplantation, respectively (. P=.009). In multivariate analysis, poor-risk cytogenetics was associated with relapse (hazard ratio, 1.7 [95% confidence interval, 1.0 to 3.0]; P=.04) and worse leukemia-free survival (hazard ratio, 1.6 [95% confidence interval, 1.0 to 2.5]; P=.03), whereas donor choice had no significant impact on overall survival (. P=.73). Adjusted 3-year overall survival rates were 55% with SIB, 45% with URD, and 43% with UCB transplantation (. P=.26). Until prospective studies are completed, this study supports the recommendation to consider SIB donor, URD, or UCB for HCT for older patients with AML in complete remission.
KW - Acute myeloid leukemia
KW - Cord blood
KW - Older patients
KW - Reduced-intensity conditioning regimen
KW - Unrelated donor
UR - http://www.scopus.com/inward/record.url?scp=84882762856&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84882762856&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2013.06.006
DO - 10.1016/j.bbmt.2013.06.006
M3 - Article
C2 - 23791622
AN - SCOPUS:84882762856
SN - 1083-8791
VL - 19
SP - 1355
EP - 1360
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 9
ER -